Status: Finalised
First registered on:
11/03/2016
Last updated on:
12/07/2016
1. Study identification
EU PAS Register NumberEUPAS12762
Official titleIncidence of oral thrush in COPD patients prescribed ICS as part of ICS/LABA therapy
Study title acronym
Study typeObservational study
Brief description of the studyA historical cohort, UK database study in patients with COPD comparing the incidence of oral thrush in those prescribed ICS as part of fixed-dose combination ICS/LABA therapies, with that in patients prescribed long-acting bronchodilator therapies without ICS
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupResearch in Real Life Ltd
Organisation/affiliationOPRI Pte Ltd
Details of (Primary) lead investigator
Title Miss
Last name Wood
First name Lucy
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed26/02/201505/03/2015
Start date of data collection07/04/201507/04/2015
Start date of data analysis07/04/201507/04/2015
Date of interim report, if expected12/05/201512/05/2015
Date of final study report30/05/201629/06/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesTEVA Pharmaceutical Industries100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
Postcode
CountryUnited Kingdom
Phone number (incl. country code)44-1223967582
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Price
First name David
Address line 15a Coles Lane
Address line 2Oakington
Address line 3
CityCambridge
Postcode
CountryUnited Kingdom
Phone number (incl. country code)44-1223967582
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Product NameSymbicort
CountryUnited Kingdom
Substance INN(s)BUDESONIDE
FORMOTEROL FUMARATE DIHYDRATE
Product NameSeretide
CountryUnited Kingdom
Substance INN(s)FLUTICASONE PROPIONATE
SALMETEROL XINAFOATE
7. Medical conditions to be studied
Medical condition(s)Yes
Chronic obstructive pulmonary disease
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects22808
Additional information
Phase 1: unmatched analysis of 13,647 patients prescribed FDC ICS/LABA plus 9,161 patients prescribed LABA and/or LAMA. Matched analysis of 8,255 randomised pairs (16,510 total).
Phase 2: matched analysis of 3,465 randomised pairs for Symbicort/Seretide DPI cohort (6,930 total). Matched analysis of 3,800 randomised pairs for Seretide pMDI/Seretide DPI cohort (7,600 total).
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Routine primary care electronic patient registry
11. Scope of the study
What is the scope of the study?
Observational study
Primary scope : Observational study
12. Main objective(s)
What is the main objective of the study?
The aim of the study is two-fold: first, to investigate whether there is an association between ICS use as part of an FDC ICS/LABA and oral thrush in patients with COPD (Phase 1); and second, to assess whether this potential relationship between FDC ICS/LABA use and oral thrush is modulated by the ICS drug and dose within the prescribed FDC device (Phase 2).
Are there primary outcomes?Yes
Incidence of oral thrush, defined as the proportion of patients with a diagnosis and/or prescribed medication for treating oral thrush within the outcome period.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
Statistically significant results will be defined as p<0.05 and trends as 0.05≤p<0.10. Summary statistics will be produced for all baseline and outcome variables, as a complete dataset and for each matched cohort. All two-way comparisons of the primary outcome between treatment arms will be analysed using conditional logistic regression. Results will be reported as both: number (%) of patients diagnosed/prescribed therapy for oral thrush; and the odds ratio (95% CI), crude and adjusted for baseline predictors/confounders. The 5% level of significance will be used (two-tailed test).
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
